Tuberous sclerosis complex: From Drosophila to human disease

Trends in Cell Biology

Volumn 14, Issue 2, 2004, Pages 78-85

  Pan, Duojia ^a   Dong, Jixin ^a   Zhang, Yong ^a   Gao, Xinsheng ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NEUROMODULIN; TUBERIN;

CELL ACTIVATION; CELL GROWTH; DROSOPHILA; DRUG TARGETING; EXPERIMENTAL MODEL; GENE ACTIVATION; GENE FUNCTION; GENE INTERACTION; MAMMAL CELL; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TUBEROUS SCLEROSIS; TUBEROUS SCLEROSIS COMPLEX 1 GENE; TUBEROUS SCLEROSIS COMPLEX 2 GENE; TUMOR SUPPRESSOR GENE;

MAMMALIA;

EID: 0442323560     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcb.2003.12.006     Document Type: Review

References (84)

1. Young J., Povey S. The genetic basis of tuberous sclerosis. Mol. Med. Today. 4:1998;313-319.
2. van Slegtenhorst M., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 277:1997;805-808.
3. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 75:1993;1305-1315.
4. Soucek T., et al. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15653-15658.
5. Soucek T., et al. Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J. Biol. Chem. 272:1997;29301-29308.
6. Xiao G.-H., et al. The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J. Biol. Chem. 272:1997;6097-6100.
7. Lamb R.S., et al. The TSC1 tumor suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat. Cell Biol. 2:2000;281-287.
8. Henry K.W., et al. Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members. J. Biol. Chem. 273:1998;20535-20539.
9. Nellist M., et al. Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin. J. Biol. Chem. 274:1999;35647-35652.
10. van Slegtenhorst M., et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet. 7:1998;1053-1057.
11. Kobayashi T., et al. Transgenic rescue from embryonic lethality and renal carcinogenesis in the Eker rat model by introduction of a wild-type Tsc2 gene. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3990-3993.
12. Rennebeck G., et al. Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15629-15634.
13. +/- mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104:1999;687-695.
14. Kobayashi T., et al. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res. 59:1999;1206-1211.
15. Kobayashi T., et al. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc. Natl. Acad. Sci. U. S. A. 98:2001;8762-8767.
16. Kwiatkowski D.J., et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11:2002;525-534.
17. Matsumoto S., et al. Role of the Tsc1-Tsc2 complex in signaling and transport across the cell membrane in the fission yeast Schizosaccharomyces pombe. Genetics. 161:2002;1053-1063.
18. Neufeld T.P., et al. Coordination of growth and cell division in the Drosophila wing. Cell. 93:1998;1183-1193.
19. Weigmann K., et al. Cell cycle progression, growth and patterning in imaginal discs despite inhibition of cell division after inactivation of Drosophila Cdc2 kinase. Development. 124:1997;3555-3563.
20. Proud C.G., Denton R.M. Molecular mechanisms for the control of translation by insulin. Biochem. J. 328:1997;329-341.
21. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A. 96:1999;4240-4245.
22. Thomas G., Hall M.N. TOR signalling and control of cell growth. Curr. Opin. Cell Biol. 9:1997;782-787.
23. Gingras A.C., et al. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15:2001;807-826.
24. Shioi T., et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19:2000;2537-2548.
25. Shioi T., et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 22:2002;2799-2809.
26. Rommel C., et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3:2001;1009-1013.
27. Shima H., et al. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 17:1998;6649-6659.
28. Leevers S.J., et al. The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J. 15:1996;6584-6594.
29. Böhni R., et al. Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1-4. Cell. 97:1999;865-875.
30. Verdu J., et al. Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB. Nat. Cell Biol. 1:1999;500-506.
31. Huang H., et al. PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development. Development. 126:1999;5365-5372.
32. Goberdhan D.C.I., et al. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. 13:1999;3244-3258.
33. Gao X., et al. Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways. Dev. Biol. 221:2000;404-418.
34. Rintelen F., et al. PDK1 regulates growth through Akt and S6K in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 98:2001;15020-15025.
35. Cho K.S., et al. Drosophila phosphoinositide-dependent kinase-1 regulates apoptosis and growth via the phosphoinositide 3-kinase-dependent signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 98:2001;6144-6149.
36. Montagne J., et al. Drosophila S6 kinase: a regulator of cell size. Science. 285:1999;2126-2129.
37. Ito N., Rubin G.M. gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell. 96:1999;529-539.
38. Tapon N., et al. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell. 105:2001;345-355.
39. Potter C.J., et al. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell. 105:2001;357-368.
40. Gao X., Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 15:2001;1383-1392.
41. Hara K., et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 273:1998;14484-14494.
42. Dennis P.B., et al. Mammalian TOR: a homeostatic ATP sensor. Science. 294:2001;1102-1105.
43. Kim D.H., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 110:2002;163-175.
44. Hara K., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 110:2002;177-189.
45. Nave B.T., et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344:1999;427-431.
46. Fang Y., et al. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 294:2001;1942-1945.
47. Mills G.B., et al. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:2001;10031-10033.
48. Neshat M.S., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U. S. A. 98:2001;10314-10319.
49. +/- mice. Proc. Natl. Acad. Sci. U. S. A. 98:2001;10320-10325.
50. Zhang H., et al. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev. 14:2000;2712-2724.
51. Oldham S., et al. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev. 14:2000;2689-2694.
52. Gao X., et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 4:2002;699-704.
53. Radimerski T., et al. Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev. 16:2002;2627-2632.
54. Inoki K., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:2002;648-657.
55. Tee A.R., et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. U. S. A. 99:2002;13571-13576.
56. Boguski M.S., McCormick F. Proteins regulating Ras and its relatives. Nature. 366:1993;643-654.
57. Wienecke R., et al. Identification of tuberin, the tuberous sclerosis-2 product: tuberin possesses specific Rap1GAP activity. J. Biol. Chem. 270:1995;16409-16414.
58. Kobayashi T., et al. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat. Genet. 9:1995;70-74.
59. Yeung R.S., et al. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc. Natl. Acad. Sci. U. S. A. 91:1994;11413-11416.
60. Dabora S.L., et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 68:2001;64-80.
61. Maheshwar M.M., et al. The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis. Hum. Mol. Genet. 6:1997;1991-1996.
62. Saucedo L.J., et al. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell Biol. 5:2003;566-571.
63. Stocker H., et al. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol. 5:2003;559-566.
64. Patel P.H., et al. Drosophila Rheb GTPase is required for cell cycle progression and cell growth. J. Cell Sci. 116:2003;3601-3610.
65. Zhang Y., et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5:2003;578-581.
66. Garami A., et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell. 11:2003;1457-1466.
67. Tee A.R., et al. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13:2003;1259-1268.
68. Inoki K., et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17:2003;1829-1834.
69. Castro A.F., et al. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapam. J. Biol. Chem. 278:2003;32493-32496.
70. Sekulic A., et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60:2000;3504-3513.
71. Potter C.J., et al. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4:2002;658-665.
72. Manning B.D., et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell. 10:2002;151-162.
73. Peng X.D., et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 17:2003;1352-1365.
74. Radimerski T., et al. dS6K-regulated cell growth is dPKB/dPI(3)K- independent, but requires dPDK1. Nat. Cell Biol. 4:2002;251-255.
75. Lizcano J.M., et al. Insulin-induced Drosophila S6 kinase activation requires phosphoinositide 3-kinase and protein kinase B. Biochem. J. 374:2003;297-306.
76. Prober D.A., Edgar B.A. Interactions between Ras1, dMyc, and dPI3K signaling in the developing Drosophila wing. Genes Dev. 16:2002;2286-2299.
77. Oldham S., Hafen E. Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol. 13:2003;79-85.
78. Urano J., et al. The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake. J. Biol. Chem. 275:2000;11198-11206.
79. Inoki K., et al. TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival. Cell. 115:2003;577-590.
80. Tabancay A.P. Jr, et al. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J. Biol. Chem. 278:2003;39921-39930.
81. Clark G.J., et al. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J. Biol. Chem. 272:1997;10608-10615.
82. Cox A.D., Der C.J. Farnesyltransferase inhibitors: promises and realities. Curr. Opin. Pharmacol. 2:2002;388-393.
83. Rubin G.M., et al. Comparative genomics of the eukaryotes. Science. 287:2000;2204-2215.
84. Jaeschke A., et al. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol. 159:2002;217-224.